|Bid||114.00 x 800|
|Ask||117.18 x 1000|
|Day's Range||115.40 - 116.61|
|52 Week Range||100.22 - 120.06|
|PE Ratio (TTM)||4.04|
|Expense Ratio (net)||0.47%|
Shares of Gemphire Therapeutics Inc. (gemp) plunged 17% toward a record low Friday after the biopharmaceutical company said a phase 2a trial of its treatment for non-alcoholic fatty liver disease in pediatric patients will be terminated, citing "unanticipated problems." The company said the data and safety monitoring board at Emory University overseeing the trial recommended the termination. Gemphire said data on the first three patients undergoing 12 weeks of treatment all experienced an increase in liver fat content, which was deemed an unexpected problem.
BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.
Ionis Pharmaceuticals (IONS), one of the leading biopharmaceutical companies, is focused on developing RNA-targeted therapies. Ionis has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. Ionis missed Wall Street analyst estimates and reported earnings per share of -$0.29 on revenues of $117.7 million during Q2 2018 as compared to EPS estimates of -$0.09 on revenues of $135.5 million during the quarter.
Shares of Ampio Pharmaceuticals Inc. (ampe) plunged 69% in morning trade Wednesady, to fall back below the $1 threshold for the first time in 10 months, after the biopharmaceutical company said the Food and Drug Administration said a current trial for a treatment of osteoarthritis of the knee did not support a biologics license application (BLA). The FDA said the that as a single trial, the AP-003-A trial on its own does not appear to provide sufficient evidence of effectiveness to support a BLA. The FDA recommended an additional randomized trial.
Biotechnology investors are no strangers to volatility, and Tuesday's price action was no exception. Followers of gene therapy companies watched one of the most popular names in the industry lose approximately one-third of its value due to patient safety concerns. As alluded to above, shares of Spark Therapeutics dropped sharply in Tuesday's trading session due to heightened patient safety concerns surrounding a hemophilia gene therapy trial.
BeiGene (BGNE) reported revenues of $32.5 million and EPS of -$2.03 in the first quarter. Analysts expect BeiGene to report EPS of -$2.06 on revenues of $22.5 million during the second quarter. This represents 100.0% growth in its YoY (year-over-year) revenues, compared to zero revenues during the second quarter of 2017. The chart below compares analysts’ recommendations over the last 12 months.
As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.
Biotechnology sector ETFs were among the best performers Tuesday, with Illumina (ILMN) shares surging after the genomics firm beat second-quarter expectations and raised its year-end outlook. Among the best performing ETFs of Tuesday, the Invesco Dynamic Biotech & Genome (PBE) increased 3.0%, ARK Genomic Revolution Multi-Sector ETF (ARKG) advanced 2.5% and iShares Nasdaq Biotechnology ETF (IBB) rose 2.0%. Evercore analyst Ross Muken said in that the Illumina stock story is "far too compelling to ignore," reports Allison Gatlin for Investor's Business Daily.
Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.
Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates. It reported non-GAAP EPS of $3.83 on revenue of ~$6.1 billion, while analysts had expected EPS of $3.54 on revenue of $5.7 billion. The chart below shows Amgen’s EPS and revenue since Q1 2017.
In the second quarter of 2018, Celgene (CELG) reported revenues of $3.8 billion, compared to $3.3 billion in the second quarter of 2017, reflecting ~17% growth on a year-over-year (or YoY) basis and ~8% growth sequentially.
Shares of resTORbio Inc. (torc) nearly tripled in premarket trade Wednesday, after the biopharmaceutical company announced positive results from its dose-ranging phase 2b trial of its treatment for respiratory tract infections (RTIs). The company said RTB101 demonstrated a statistically significant and clinically meaningful reduction in the percentage of patients with one or more RTIs during the treatment period, the primary endpoint of the study with the 10 mg once-daily dose, while RTB101 10 mg in combination with everolimus 0.1 mg didn't meet the primary endpoint.
MARKET PULSE Exchange-traded funds tracking the biotechnology sector rallied on Tuesday, supported by stronger-than-expected quarterly results from a pair of major components. The iShares Nasdaq Biotechnology ETF (IBB) gained 1.
As discussed previously, analysts expect Amgen’s (AMGN) revenue to fall 1.3% YoY (year-over-year) to $5.7 billion in Q2 2018. The graph below shows Amgen’s revenue since Q1 2017, and Q2 2018 estimates. While new product sales are expected to see double-digit growth, legacy product sales are expected to fall.
Netflix failed to meet market expectations, posting disappointing subscriber adds and lowering third-quarter targets.
Pfizer (NYSE:PFE) was the target of a Presidential tweet tantrum Monday over its second price hike of the year but investors shrugged it off.
Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq ...
Biogen (NASDAQ:BIIB) is the hot stock of the moment thanks to success in a trial of an Alzheimer’s drug. Progress on Alzheimers makes Biogen stock worth at least a look, right? Both follow the so-called “amyloid hypothesis,” the idea that reducing amyloid plaques using monoclonal antibodies can reverse the disease.
MARKET PULSE Exchange-traded funds that track the biotechnology sector jumped on Friday, supported by a huge gain in industry bellwether Biogen, which climbed after a positive drug trial. The iShares Nasdaq Biotechnology ETF (IBB) jumped 2.
First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.
Pfizer (NYSE:PFE) is a pharma/biotech dinosaur. This stock is a survivor of decades of stock market turmoils and corrections. It currently sits on a potential long-term technical breakout point on the monthly chart.
Are shares of Celgene Corporation (NASDAQ:CELG) finally bottoming? Without news flow for the stock to react on, it’s hard to confirm whether the peak-to-trough drop of 49.6% in CELG stock is over or if more losses are still to come. Celgene is far from perfect.
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after United Health Group reports second quarter net income that beat Wall Street expectations. Here's the performance of select health care stocks as of 10:00 am ET: JNJ Johnson & Johnson 3.67% NKTR(0) Nektar Therapeutics 1.36% ABT Abbott Laboratories 1.07% HCA HCA Hldg Inc 0.88% LLY Lilly (Eli) 0.79% ALXN Alexion Pharmaceuticals 0.80% CELG Celgene Corp 0.72% COO Cooper Cos 0.54% BIIB Biogen Inc 0.54% PFE Pfizer Inc 0.49% BSX Boston Scientific Corporation 0.54% MDT Medtronic plc 0.42% SYK Stryker Corp 0.51% PRGO(HB) Perrigo Co plc 0.35% IBB iShs Nasdaq BioTech ETF 0.37% BMY Bristol-Myers SQUIBB 0.35% EVHC Envision Healthcare Corp 0.34% VAR Varian Medical Systems Inc 0.28% UHS Univl Health Svs'B' 0.24% MRK Merck & Co 0.16% ZTS Zoetis Inc 0.22% BAX Baxter Intl Inc 0.18% INCY Incyte Corp 0.10% BDX Becton, Dickinson 0.15% REGN Regeneron Pharmaceuticals 0.08% IDXX Idexx Laboratories 0.16% VRTX Vertex Pharmaceuticals 0.11% ABMD Abiomed, Inc 0.03% SHPG Shire plc ADS 0.12% BMRN Biomarin Pharmaceutical 0.10% XRAY Dentsply Sirona Inc 0.09% GILD Gilead Sciences 0.03% XLV S&P Sel Health Care Spdr Fd 0.02% ISRG Intuitive Surgical -0.03% ABC AmeriSourceBergen Corp -0.10% IQV IQVIA Hldgs Inc 0.01% ZBH Zimmer Biomet Hldgs Inc -0.04% HOLX Hologic Inc 0.00% DGX Quest Diagnostics -0.14% ALGN Align Tech 0.11% AGN Allergan plc -0.31% TMO Thermo Fisher Scientific Inc -0.17% HSIC Henry Schein Inc -0.24% EW Edwards Lifesciences Corp -0.19% RMD Resmed Inc -0.21% AET Aetna Inc -0.40% MCK McKesson Corp -0.54% ABBV AbbVie Inc -0.34% DVA DaVita Inc -0.48% MYL Mylan NV -0.49% CAH Cardinal Health Inc -0.71% AMGN Amgen Inc -0.68% LH Laboratory Corp Amer Hldgs -0.68% CNC Centene Corp -1.75%